Drug Trial Radar · NCT07659379
Gotistobart Long Term Extension (LTE) Study
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Jul 1, 2036
Study completion Jan 1, 2037
Sponsor
- Lead sponsor
- OncoC4, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
GotistobartDrug
ONC-392 will be given following parent trial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: 240 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Texas Oncology - Fort Worth Cancer Center (USOR)
Fort Worth, Texas
Texas Oncology - Northeast
Tyler, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.